Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
|
|
- Agatha Chambers
- 5 years ago
- Views:
Transcription
1 Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel
2 HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5 out of 36.7 million people living with HIV in 2015 are in Africa Progress is being made New UNAIDS data show the drop in new infections worldwide has leveled off since 2010 Key populations, including women and girls in Africa, still at high risk of HIV infection - o Leading cause of death globally among women ages o In parts of sub-saharan Africa, young women are more than twice as likely be infected with HIV as young men 2 June 2017
3 Women s Vulnerability to HIV Gender inequities, including gender-based and intimate partner violence Condom use can be difficult to negotiate Financial dependence on male partners Young women at even higher risk Early marriage, intergenerational sex and concurrent partnerships Limited access to SRH information and health services Higher male-to-female transmission Biological Economic Socio- Cultural
4 HIV Prevention Toolkit Male and female condoms Behavior change Prevention of mother-to-child transmission Voluntary medical male circumcision Post-exposure prophylaxis (PEP) Treatment as prevention (TasP) Oral pre-exposure prophylaxis (PrEP) Vaginal rings Rectal microbicides Injectable ARVs HIV vaccines 4 June 2017
5 HIV Prevention Trials: Efficacy Results Male circumcision men South Africa MCB -Savvy gel women West Africa Male circumcision men Kenya Male circumcision men Uganda MCB -CS gel women Africa, India Male Circumcision MCB Carraguardwomen South Africa MCB -PRO 2000 gel and BufferGel women Africa, USA Vaccine -RV144 men and women Thailand MCB -PRO 2000 gel women Africa PrEP- oral Truvada (FEM-PrEP) women Africa TasP-HPTN 052 couples Global PrEP-oral Truvada and TFV (Partners PrEP) couples Africa PrEP-oral Truvada men, women Botswana Oral PrEP PrEP-Oral tenofovir IDUs Thailand PrEP- oral Truvada (VOICE) women Africa Vaccine VRC DNA/rAd5 MSM, transgender USA PrEP- Oral Truvada (iprexole) MSM, transgender Global MCB -Tenofovir gel (FACTS 001) women Africa PrEPand ART Oral Truvada (Partners PrEPdemo) couples Dapivirine Africa Vaginal Ring Dossier in progress MCB -Dapivirine Vaginal Ring (ASPIRE) women Africa Male circumcision women Uganda MCB -tenofovir gel (CAPRISA 004) women South Africa PrEP- oral tenofovir (VOICE) women Africa PrEP-Oral Truvada (PROUD) MSM United Kingdom Vaccine - Step/Phambili men and women Global PrEP-oral Truvada (iprex) MSM Global MCB -tenofovir gel (VOICE) women Africa PrEP-oral Truvada (Ipergay) MSM Canada, France MCB -Dapivirine Vaginal Ring (The Ring Study) women Africa June 2017
6 Dapivirine Ring Development Path Dapivirine Dapivirine licensed to IPM in 2004 from Janssen Sciences Ireland UC; expanded to exclusive worldwide rights in 2014 Dapivirine Ring IPM developed and manufactured the first dapivirine ring IPM regulatory sponsor Product Development Plan Regulatory Path Regulatory Dossier Regulatory Approval Access Plan Drug Development Plan consistent with Regulatory Path World Medical Association Declaration of Helsinki International Conference on Harmonisation Guideline for Good Clinical Practice US Food and Drug Administration Country Specific Regulatory Authority Guidelines & Regulations 6 June 2017
7 Clinical Development Dapivirine Ring: Clinical Development Plan Phase I Phase II Phase III Phase IIIB IPM 024 First Ring-004 in Women IPM 013 Multiple Rings in Women IPM 034 Extended Ring use in Women IPM 035 Menses and Tampon Use IPM 036 DDI with Clotrimazole* MTN-029/IPM 039 PK in lactating women* IPM 011 Single Placebo Ring over 3 months in Women in Africa IPM 015 Multiple Rings in Women in Africa MTN-024/IPM 031 Post Menopausal IPM 027 (The Ring Study) Open-Label* Amendment 5.0 MTN-020 (ASPIRE) IPM 032 (DREAM) Open label extension+ Cohorts of ring naïve young women (18 25 years) MTN-025 (HOPE) Open label extension+ IPM 028 DDI with Miconazole Nitrate MTN-012/IPM 010 Male tolerance study (Gel 4759) MTN-023/IPM 030 Adolescents in US* IPM 029 & IPM 033 Condom Functionality *In analysis +Ongoing #Planned Additional arm, measuring PK levels with intermittent ring use 7 June 2017 MTN/IPM Pregnant and Breast feeding women # MTN-034/IPM 045 Ring naïve young women in Africa# (16-21 years)
8 Dapivirine Vaginal Ring, 25 mg Approximately 4 mg dapivirine is released during continuous use over a month Dapivirine residual levels in used rings decrease with the duration of ring use High dapivirine vaginal fluid concentrations: Achieved by 24 hours Maintained throughout the entire month of use Very low plasma concentrations 8 June 2017
9 Phase III Dapivirine Vaginal Ring Reduces HIV-1 infection risk in two independent wellcontrolled Phase III clinical trials in women ages years in sub-saharan Africa 31% reduction 9 June 2017 P < 0.05, statistically significant
10 Phase III Dapivirine Vaginal Ring Reduces HIV-1 infection risk in two independent wellcontrolled Phase III clinical trials in women ages years in sub-saharan Africa 27.4% HIV reduction CI: 8.6%; 42.3% p= June 2017 Based on HIV-1 Seroconversion (HIV Rapid Test Result)
11 HIV Prevention Trials: Varying Levels of Efficacy Study Effect size (CI) TDF/FTC (Partners PrEP Demo) 94% (85, 98) TasP (HPTN052) 93% (78, 98) TDF/FTC (PROUD) 86% (58, 96)* TDF/FTC (Ipergay) 86% (40, 99) TDF/FTC (Partners PrEP) 75% (55, 87) TDF (Partners PrEP) 67% (44, 81) TDF/FTC (TDF2, CDC) 62% (22, 83) Medical male circumcision 57% (29, 76) (Orange Farm, Rakai, Kisumu) TDF (Bangkok TDF Study) 49% (10, 72) TDF/ FTC (iprex) 44% (15, 63) Tenofovir gel (CAPRISA 004) 39% (6, 60) Prime-boost Vaccine (Thai RV144) 31% (1, 52) Dapivirine ring (The Ring Study) 31% (1, 52) Dapivirine ring (ASPIRE) 27% (1, 46) TDF/ FTC (FEM-PrEP) 6% (-52, 41) Prime-boost Vaccine -25%(-121, 29) (HVTN 505) Tenofovir gel 15% (-20, 40) TDF -4%(-49, 27) TDF/FTC -49%(-122, 3) Tenofovir gel (FACTS 001) 0% (-60, 40) (VOICE) *90% confidence interval 11 June 2017
12 Dapivirine Vaginal Ring, 25 mg: Efficacy Adherence to Use Objective measures of non-adherence to ring use: Dapivirine residual levels in used rings Dapivirine plasma and vaginal fluid concentrations All measures are imperfect as they cannot distinguish different patterns of ring use during the month None of the measures indicate if the ring was used during the time of an HIV risk event No HIV-1 infection risk reduction is observed when women do not adhere to ring use (dapivirine residual levels >23.5mg or plasma concentrations <95pg/ml) Higher HIV-1 risk reduction is achieved with increased adherence to product use Continuous use, including during menses is very important If removed, the ring should immediately be replaced by a new ring 12 June 2017
13 Dapivirine Vaginal Ring: Safety Dapivirine vaginal ring is safe No difference between the dapivirine and placebo groups in the number of:» pregnancies and pregnancy outcomes» adverse events (side effects / health problems)» sexually transmitted infections and bacterial vaginosis No significant HIV-1 drug resistance Male and Female condoms can be used with the ring 13 June 2017 Vaginal miconazole can be used concomitantly with the ring
14 The Next Step for the Dapivirine Vaginal Ring? Regulatory Pathway Public Health Pathway Applications for regulatory approval will be submitted starting mid 2017 Two open-label extension trials to support consistent use Access 14 June 2017
15 Open-Label Extension Trials Activated in July 2016 for former Phase III participants Assessment of adherence to ring use and long-term safety profile Adolescentclinical trial planned for 2017: Assess safety of and adherence to Dapivirine Vaginal Ring and oral PrEP among 300 young women, years, in Kenya, South Africa, Uganda, Zimbabwe (MTN-034/IPM 045) 15 June 2017
16 Open-Label Extension Trials (Phase IIIb) DREAM (IPM 032) HOPE(MTN-025) Treatment Regimen 25 mg Dapivirine Vaginal Ring, replaced monthly Design Follow-up regimens Product use period Phase III former Participants, Open-label Follow-up visit one month after enrolment up to three months 3-monthly visit schedule: three rings dispensed to the participant two additional to take home, or dispensing will take place as arranged with the participant Approx. 1-year follow-up with extension Approx. 1-year 16 June 2017
17 DREAM (IPM 032): Ring-use Naïve Participant Cohorts No HIV risk reduction was observed in younger women in the Phase III program, a protocol amendment includes: two additional cohorts of young women 18 to 21 years and >21 to <25 years who have not used the Dapivirine Vaginal Ring-004 previously 300 participants per cohort BETTER UNDERSTANDING OF UNIQUE CHALLENGES Additional data will be collected to gain a better understanding of younger women s unique challenges in using HIV prevention methods 17 June 2017
18 Qualitative Component In-depth interviews: Decliner population Ring users Ring non-users Cases of interest Male partners Male community members DVR-naïve cohorts: Baseline behavioural assessment ACCEPTABILITY AND INFLUENCERS OF RING USE Behavioural data will support the potential introduction of a microbicide as a public health intervention and assist with future program development. 18 June 2017
19 Women Need Multiple Options Women-initiated technologies are a key component of a comprehensive prevention package No one option will suit everyone To end the HIV epidemic, women need multiple options that meet their various needs, including daily oral PrEP, long-acting vaginal rings and one day, rectal microbicides, injectablesand vaccines 19 June 2017
20 Regulatory Pathway European Medicines Agency (EMA) Article 58 eligibility reconfirmed 2016 (Co) Rapporteur meetings Jan 2017 Pre-submission meeting Feb 2017 Target submission end Q World Health Organization (WHO) Why WHO Prequalification? Process to evaluate whether a drug meets global standards o Quality o Safety o Efficacy Many African regulatory agencies use WHO prequalification to determine which new products to approve, and review EMA decisions Sub-Saharan NRAs Following WHO PQ, first round of submissions to Kenya, Malawi, Rwanda, Tanzania, Uganda, Zambia and Zimbabwe Medicines Control Council (MCC, SA) Target submission Q US Food and Drug Administration (FDA) Target submission June 2017
21 It takes a village to develop the Dapivirine Ring Trial Participants Research Centre Teams and Leadership Partners, Vendors and Collaborators National and Local Leaders and Stakeholders MTN, DAIDS, NIH Colleagues Colleagues of Janssen Sciences Ireland UC IPM Board, Management and Colleagues Our Family and Friends 21 June 2017
22 Current IPM Donors The contents of this presentation are the responsibility of IPM and do not necessarily reflect the views of its donors. 22 June 2017
23 Contact Information: Dr Annalene Nel International Partnership for Microbicides Tel: / anel@ipmglobal.org.za Website:
From Ring to DREAM Mariëtte Malherbe IPM, Clinical Support Manager
From Ring to DREAM Mariëtte Malherbe IPM, Clinical Support Manager MTN Regional Meeting Plenary Meeting 19 September 2017 Overview From Ring to DREAM Women s Vulnerability to HIV Women Need Multiple Options
More informationUnderstanding the Results of VOICE
CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF
ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV
More informationAntiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?
Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated
More informationUpdate on ARV based PrEP
Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV
More informationThe Big Picture: The current and evolving HIV prevention landscape
The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationNovel HIV Prevention Methods for Women
Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health
More informationPre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012
New biomedical technologies. Pre-exposure prophylaxis : Systemic and topical. Linda-Gail Bekker The Desmond Tutu HIV Centre UCT SA HIV ClniciansSociety Conference 2012 And the last parachute goes to..
More informationOverview of ARV-based prevention trials
Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationWhat do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women
What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety
More informationARVs for prevention in at-risk populations: Microbicides
ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):
More informationAdolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017
Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa Jessica Haberer, MD, MS November 9, 2017 Disclosures I have no conflicts to declare Grant funding: NIH, Gates
More informationInternational Partnership for Microbicides
International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March
More informationPre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:
Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationWhere We Have Been and Where We are Going. Ian McGowan MD PhD FRCP
Where We Have Been and Where We are Going Ian McGowan MD PhD FRCP Directions Where we were Where we are headed Where we are 2005 The size of your dreams must always exceed your current capacity to achieve
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Advancing HIV Prevention Options for Women GNP+ Consultation on NPTs Thomas Mertenskoetter 5. 6. July 2010, Amsterdam Leading Causes of Death in Women (Age 15
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More informationDrug development in relation to PrEP and the PROUD study
Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals
More informationPre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention
Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure
More informationAntiretrovirals for HIV prevention:
Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationUpdate on PrEP progress: WHO/UNAIDS challenges and actions
Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure
More informationHIV In South Africa: Turning the Tide of the Epidemic
HIV In South Africa: Turning the Tide of the Epidemic Jean B. Nachega, MD, PhD Associate Professor Department of Epidemiology Pittsburgh University, Graduate School of Public Health E-mail: JBN16@PITT.EDU
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationTranslating the Science to End New HIV Infections in Kenya
Translating the Science to End New HIV Infections in Kenya Perspectives, Practices and Lessons Nairobi, 28-30 May 2017 www.iasociety.org AIDS 2016 Post-Conference Workshop Setting the Stage Overview of
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationMTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in
More informationPREPARING FOR PREP: FROM KEY POPULATIONS THEORY TO PRACTICE. Dr Oscar Radebe
PREPARING FOR PREP: FROM THEORY TO PRACTICE KEY POPULATIONS Dr Oscar Radebe PrePARINGFOR THE END OF HIV Until recently there has been exciting new advances in clinical research focusing on HIV prevention
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationThe Open Label Trial Past and Present
The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationTasP - Individual versus Public Health Benefit versus Both.
Site Map l Contact Us l Calendar l Join AVAC Donate TasP - Individual versus Public Health Benefit versus Both. Kevin Fisher Policy Director, AVAC June 2012 Multiple choice answer: all of the above We
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationThe HIV Prevention Product Pipeline for Adolescents JANUARY 8 TH, 2018
The HIV Prevention Product Pipeline for Adolescents SYBIL HOSEK, PHD DEPARTMENT OF PSYCHIATRY, STROGER HOSPITAL OF COOK COUNTY I NTER-CFAR ARV FOR PREVENTION WORKING GROUP WEBINAR JANUARY 8 TH, 2018 Conflicts
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update
More informationBiomedical Prevention in HIV
Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa
More informationWelcome and State of the Network. Cape Town, South Africa 27 th September 2016
Welcome and State of the Network Cape Town, South Africa 27 th September 2016 The HIV/AIDS Epidemic in 2016 17 million people were accessing antiretroviral therapy 36.7 million people globally were living
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationUnderstanding the Impact of an HIV Intervention Package for Adolescents
Understanding the Impact of an HIV Intervention Package for Adolescents Faikah Bruce Supervisors: Dr. Leigh Johnson (UCT - CIDER) and Prof. Alex Welte (SU - SACEMA) 1 Contents Introduction Literature Review
More informationQUESTIONS AND ANSWERS
CONTACTS: Clare Collins Lisa Rossi +1-412-641-7299 +1-412-641-8940 +1-412-770-8643 (mobile) +1-412-916-3315 (mobile) collcx@upmc.edu rossil@upmc.edu QUESTIONS AND ANSWERS MTN-016: HIV Prevention Agent
More informationMTN 034/IPM 045: REACH Rings and PrEP in Young Women
MTN 034/IPM 045: REACH Rings and PrEP in Young Women Lulu Nair CRS Leader: Emavundleni -Cape Town On behalf of MTN 034 protocol team MTN Annual Meeting: 2017 Bethesda North Marriott Hotel and Conference
More informationAbout FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.
Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose
More informationCAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina
CAN MONEY REDUCE HIV RISK?? Audrey Pettifor, PhD MPH Department of Epidemiology, University of North Carolina Overview Epidemiology of HIV in young people Rationale behind cash transfers Review completed
More informationPEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital
PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/
More informationA Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)
A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017 Presentation
More informationUpdate on Antiretroviral-Based HIV Prevention
Update on Antiretroviral-Based HIV Prevention Prof. Janneke van de Wijgert University of Liverpool, Institute of Infection and Global Health Click to edit Master subtitle style 12th European Meeting on
More informationQUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use I. ASPIRE and The Ring Study: The Basics
More informationThe HIV Prevention Pill: The State of PrEP Science and Implementation
The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationPrEP Dosing Strategies
PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity
More information11/8/2016. Moving Beyond Truvada: The (Current) Future Pipeline for PrEP. Prevention Modalities
Moving Beyond Truvada: The (Current) Future Pipeline for PrEP Raphael J. Landovitz, MD MSc Associate Professor of Medicine UCLA Center for Clinical AIDS Research & Education November 18, 2016 2 Million
More informationWhat Is the Dapivirine Ring?
What Is the Dapivirine Ring? Dr. Zeda Rosenberg, CEO Beyond Phase III: 2014 Civil Society Consultation What Are Microbicides? Products being developed to help prevent sexually transmitted HIV infection
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationImpact of the Proposed Cuts to HIV/AIDS Research. Kevin Fisher AVAC September 7, 2017
Impact of the Proposed Cuts to HIV/AIDS Research Kevin Fisher AVAC September 7, 2017 President s FY18 Budget Cuts $544 m from the FY 2017 NIH HIV/AIDS research budget levels A cut of 18.5% FY 18 Cut FY
More informationPEP and PrEP: AWAAC 2014
Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits
More informationInternational Partnership for Microbicides
International Partnership for Microbicides Female-Initiated Prevention: State of the Art Dr. Zeda F. Rosenberg German-Austrian AIDS Congress Frankfurt, Germany 29 June 2007 Women s Vulnerability to HIV
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationUnderstanding the results of CAPRISA 004
A Cascade of Hope and Questions Volume 2 Understanding the results of CAPRISA 004 Key messages CAPRISA 004 provides the first proof of concept that a microbicide (1% tenofovir gel) can reduce women s risk
More informationTransmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa
Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa FIDSSA, Cape Town, November 2017 Quarraisha Abdool Karim, PhD Associate Scientific Director: CAPRISA Professor
More informationPrEP May Cause a Revolution in HIV Prevention: Time to Get Ready
PrEP May Cause a Revolution in HIV Prevention: Time to Get Ready Thomas J. Coates PhD Michael and Sue Steinberg Professor of Global AIDS Research David Geffen School of Medicine University of California,
More informationUpdate on roll out of PrEP
Update on roll out of PrEP Dr Rachel Baggaley, Michelle Rodolph, Dr Shona Dalal, Dr Ioannis Hodges-Mameletzis WHO HIV Department Geneva, Switzerland Regulatory pathways and clinical trial design for long-acting
More informationBiomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013
Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine
More informationM2010 Pre-Conference Workshop, Pittsburgh 22 May 2010
HIV Prevention Research: The Global Picture Presented at: M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010 Salim S. Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director:
More informationQUESTIONS AND ANSWERS
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ASPIRE A Study to Prevent Infection with a Ring for Extended Use The Big Picture 1. What is the aim of
More informationSupplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location
Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations Study name and location ADAPT (HPTN 067) South Africa, Thailand, US (Harlem) Bangkok Tenofovir
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationReview of planned trials and key emerging issues for Thailand
Review of planned trials and key emerging issues for Thailand Frits van Griensven, PhD, MPH Silom Community Clinic Thailand MOPH US CDC Collaboration US Centers for Disease Control and Prevention ilom
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationHIV / AIDS. Prevention In Our Lives
HIV / AIDS Prevention In Our Lives Prevention In Our Lives: Produced by the Treatment Action Campaign. Authors: Published: September 2010 Conte n t s Introduction: Statistics on HIV in South Africa 2 Why
More informationDoing studies of ARV based
Doing studies of ARV based microbicides what s s different, what s s the same? Gonasagrie Nair, MBChB, DTM&H, MPH CAPRISA ethekwini Site Project Director & IoR VOICE Trial OVERVIEW Brief historical overview
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationPre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection
Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:
More information8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward
WORKSHOP SESSION: MAKING PREEXPOSURE PROPHYLAXIS AVAILABLE IN THE CLINIC: CONSIDERATIONS AND PATHWAYS FORWARD PRE-REGISTRATION IS REQUIRED PLEASE SEE THE CPT INFORMATION DESK IF THIS IS NOT YOUR SELECTED
More informationPrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.
PrEP for Women Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is PrEP? PrEP stands for Pre- Exposure Prophylaxis: Prophylaxis: Taking
More informationSuccessful results of clinical trials
Successful results of clinical trials Four clinical trials for HIV prevention in past two years showed different degrees of efficacy > HPTN 052 showed 96% reduction in HIV transmission from HIV infected
More informationAFRICAN AND BLACK DIASPORA GLOBAL NETWORK ON HIV AND AIDS ABDGN AIDS 2012 HIGHLIGHTS
AFRICAN AND BLACK DIASPORA GLOBAL NETWORK ON HIV AND AIDS ABDGN AIDS 2012 HIGHLIGHTS AGENDA Brief overview of ABDGN HIV and Migration Affiliated Event Black Diaspora Regional Working Group Black Diaspora
More informationVictoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143
Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak 36.7 Million 1.8 Million 1 Million NEW INFECTIONS LIVING WITH HIV DEATHS https://www.avert.org/global-hiv-and-aids-statistics.
More informationThe Evidence Base for Women
The Evidence Base for Women Dr. Busisiwe Msimanga-Radebe WHO South Africa country office ICASA 2017 Abidjan, Cote d Ivoire Combination prevention to break the cycle of HIV transmission Men
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationInternational Partnership for Microbicides. Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard
International Partnership for Microbicides Microbicides: New HIV Protection for Women Global Diseases: Voices from the Vanguard Dr. Zeda Rosenberg February 20, 2007 The Face of HIV Globally Increasingly
More informationPrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp
PrEP in young African women: Rationale & lessons from HPTN 082 (and other studiesp Connie Celum MD MPH Departments of Global Health and Medicine University of Washington Disproportionate Success in Epidemic
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationDAPIVIRINE RING THE CASE FOR ACTION RESEARCH BY
DAPIVIRINE RING THE CASE FOR ACTION RESEARCH BY About the Dapivirine Ring The monthly dapivirine ring is the first discrete, long-acting, HIV-prevention product designed specifically for women. Developed
More informationWhat s in the Biomedical Prevention Pipeline
What s in the Biomedical Prevention Pipeline HIV Endgame: Closing Gaps in the Care Cascade Toronto, 24 th October 2016 Ian McGowan MD DPhil FRCP University of Pittsburgh Pittsburgh, PA, USA Presenter Disclosure
More informationCan we treat our way out of the HIV epidemic?
Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question
More information10/05/2016. PrEP : from proof of concept to real life. E. CUA Nice university hospital
PrEP : from proof of concept to real life E. CUA Nice university hospital 1 Disclosures Received honoraria and acted as consultant : Merck, Gilead, ViiV Co-investigator: Merck, Gilead, ViiV and BMS phase
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationInternational Partnership for Microbicides. Phase III Clinical Trial Design Institute of Medicine February 6, 2007
International Partnership for Microbicides Phase III Clinical Trial Design Institute of Medicine February 6, 2007 IPM Product Development Strategy ARV-based gels, intravaginal rings, tablets, etc. Once
More information